Ulrike Korf

Dr. Ulrike Korf


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JBJan Christoph Brase
Jan Christoph Brase
MJMarc Johannes
Marc Johannes
HMHeiko Mannsperger
Heiko Mannsperger
MFMaria Fälth
Maria Fälth
JMJennifer Metzger
Jennifer Metzger
Holger SültmannHolger Sültmann
Holger Sültmann
Background: TMPRSS2-ERGgene fusions occur in about 50% of all prostate cancer cases and represent promising markers for molecular subtyping. AlthoughTMPRSS2-ERGfusion seems to be a critical event in prostate cancer, the precise functional role in cancer development and progression is still unclear.Methods: We studied large-scale gene expression profiles in 47 prostate tumor tissue samples and in 48 normal prostate tissue samples taken from the non-suspect area of clinical low-risk tumors using Affymetrix GeneChip Exon 1.0 ST microarrays.Results: Comparison of gene expression levels amongTMPRSS2-ERGfusion-positive and negative tumors as well as benign samples demonstrated a distinct transcriptional program induced by the gene fusion event. Well-known biomarkers for prostate cancer detection likeCRISP3were found to be associated with the gene fusion status. WNT and TGF-β/BMP signaling pathways were significantly associated with genes upregulated inTMPRSS2-ERGfusion-positive tumors.Conclusions: TheTMPRSS2-ERGgene fusion results in the modulation of transcriptional patterns and cellular pathways with potential consequences for prostate cancer progression. Well-known biomarkers for prostate cancer detection were found to be associated with the gene fusion. Our results suggest that the fusion status should be considered in retrospective and future studies to assess biomarkers for prostate cancer detection, progression and targeted therapy.

2 July 2012 in Oncogenesis
Verified
Journal Article
Open access
PDF file
FHF Henjes
F Henjes
CBC Bender
C Bender
SHS von der Heyde
S von der Heyde
LBL Braun
L Braun
HMH A Mannsperger
H A Mannsperger
UKUlrike Korf
Ulrike Korf
Increasing the efficacy of targeted cancer therapies requires the identification of robust biomarkers suitable for patient stratification. This study focused on the identification of molecular mechanisms causing resistance against the anti-ERBB2-directed therapeutic antibodies trastuzumab and pertuzumab presently used to treat patients with ERBB2-amplified breast cancer. Immunohistochemistry and clinical data were evaluated and yielded evidence for the existence of ERBB2-amplified breast cancer with high-level epidermal growth-factor receptor (EGFR) expression as a separate tumor entity. Because the proto-oncogene EGFR tightly interacts with ERBB2 on the protein level, the hypothesis that high-level EGFR expression might contribute to resistance against ERBB2-directed therapies was experimentally validated. SKBR3 and HCC1954 cells were chosen as model systems of EGFR-high/ERBB2-amplified breast cancer and exposed to trastuzumab, pertuzumab and erlotinib, respectively, and in combination. Drug impact was quantified in cell viability assays and on the proteomic level using reverse-phase protein arrays. Phosphoprotein dynamics revealed a significant downregulation of AKT signaling after exposure to trastuzumab, pertuzumab or a coapplication of both antibodies in SKBR3 cells but no concomitant impact on ERK1/2, RB or RPS6 phosphorylation. On the other hand, signaling was fully downregulated in SKBR3 cells after coinhibition of EGFR and ERBB2. Inhibitory effects in HCC1954 cells were driven by erlotinib alone, and a significant upregulation of RPS6 and RB phosphorylation was observed after coincubation with pertuzumab and trastuzumab. In summary, proteomic data suggest that high-level expression of EGFR in ERBB2-amplified breast cancer cells attenuates the effect of anti-ERBB2-directed antibodies. In conclusion, EGFR expression may serve as diagnostic and predictive biomarker to advance personalized treatment concepts of patients with ERBB2-amplified breast cancer.

19 February 2007 in Proteomics
Verified
Journal Article
Closed access
PDF file
CLChristian Loebke
Christian Loebke
HSHolger Sueltmann
Holger Sueltmann
CSChristian Schmidt
Christian Schmidt
FHFrauke Henjes
Frauke Henjes
SWStefan Wiemann
Stefan Wiemann
UKUlrike Korf
Ulrike Korf

10 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FGFrank Götschel
Frank Götschel
DBDaniela Berg
Daniela Berg
WGWolfgang Gruber
Wolfgang Gruber
CBChristian Bender
Christian Bender
MEMarkus Eberl
Markus Eberl
UKUlrike Korf
Ulrike Korf
Aberrant activation of Hedgehog (HH) signaling has been identified as a key etiologic factor in many human malignancies. Signal strength, target gene specificity, and oncogenic activity of HH signaling depend profoundly on interactions with other pathways, such as epidermal growth factor receptor-mediated signaling, which has been shown to cooperate with HH/GLI in basal cell carcinoma and pancreatic cancer. Our experimental data demonstrated that the Daoy human medulloblastoma cell line possesses a fully inducible endogenous HH pathway. Treatment of Daoy cells with Sonic HH or Smoothened agonist induced expression of GLI1 protein and simultaneously prevented the processing of GLI3 to its repressor form. To study interactions between HH- and EGF-induced signaling in greater detail, time-resolved measurements were carried out and analyzed at the transcriptomic and proteomic levels. The Daoy cells responded to the HH/EGF co-treatment by downregulating GLI1, PTCH, and HHIP at the transcript level; this was also observed when Amphiregulin (AREG) was used instead of EGF. We identified a novel crosstalk mechanism whereby EGFR signaling silences proteins acting as negative regulators of HH signaling, as AKT- and ERK-signaling independent process. EGFR/HH signaling maintained high GLI1 protein levels which contrasted the GLI1 downregulation on the transcript level. Conversely, a high-level synergism was also observed, due to a strong and significant upregulation of numerous canonical EGF-targets with putative tumor-promoting properties such as MMP7, VEGFA, and IL-8. In conclusion, synergistic effects between EGFR and HH signaling can selectively induce a switch from a canonical HH/GLI profile to a modulated specific target gene profile. This suggests that there are more wide-spread, yet context-dependent interactions, between HH/GLI and growth factor receptor signaling in human malignancies.

16 September 2005 in Proteomics
Verified
Journal Article
Closed access
PDF file
UKUlrike Korf
Ulrike Korf
TKThorsten Kohl
Thorsten Kohl
HZHans van der Zandt
Hans van der Zandt
RZRegina Zahn
Regina Zahn
SSSimone Schleeger
Simone Schleeger
APAnnemarie Poustka
Annemarie Poustka

1 May 2014 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Open access
RURamesh Ummanni
Ramesh Ummanni
HMHeiko A. Mannsperger
Heiko A. Mannsperger
JSJohanna Sonntag
Johanna Sonntag
MOMarcus Oswald
Marcus Oswald
ASAshwini K. Sharma
Ashwini K. Sharma
UKUlrike Korf
Ulrike Korf
The reverse phase protein array (RPPA) approach was employed for a quantitative analysis of 71 cancer-relevant proteins and phosphoproteins in 84 non-small cell lung cancer (NSCLC) cell lines and by monitoring the activation state of selected receptor tyrosine kinases, PI3K/AKT and MEK/ERK1/2 signaling, cell cycle control, apoptosis, and DNA damage. Additional information on NSCLC cell lines such as that of transcriptomic data, genomic aberrations, and drug sensitivity was analyzed in the context of proteomic data using supervised and non-supervised approaches for data analysis. First, the unsupervised analysis of proteomic data indicated that proteins clustering closely together reflect well-known signaling modules, e.g. PI3K/AKT- and RAS/RAF/ERK-signaling, cell cycle regulation, and apoptosis. However, mutations of EGFR, ERBB2, RAF, RAS, TP53, and PI3K were found dispersed across different signaling pathway clusters. Merely cell lines with an amplification of EGFR and/or ERBB2 clustered closely together on the proteomic, but not on the transcriptomic level. Secondly, supervised data analysis revealed that sensitivity towards anti-EGFR drugs generally correlated better with high level EGFR phosphorylation than with EGFR abundance itself. High level phosphorylation of RB and high abundance of AURKA were identified as candidates that can potentially predict sensitivity towards the aurora kinase inhibitor VX680. Examples shown demonstrate that the RPPA approach presents a useful platform for targeted proteomics with high potential for biomarker discovery. This article is part of a Special Issue entitled: Biomarkers: A Proteomic Challenge.